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It is well known that a number of assay-related issues can
affect the performance of cardiac troponin (cTn)2 mea-
surement in everyday practice. In this respect, it is vital
that all information on the cTn assays is given and that
performance characteristics of the assays are objectively
assessed and adequately described. The advent of the lat-
est generation of more sensitive cTn assays has heralded a
new wave of information about low concentrations of
cTn in blood. Those recent generation assays have im-
proved analytical sensitivity and corresponding perfor-
mance at low cTn concentrations compared with their
predecessors, providing a convincing goal for laboratory
medicine by allowing the safe clinical application of in-
ternational recommendations for the definition of acute
myocardial infarction (AMI) (1 ).
Crucial to the utility of biomarkers is laboratorians’
role in closely scrutinizing proposed assays and defining
their clinical value according to the available evidence.
Analytical, as well as preanalytical and postanalytical, as-
pects must be documented. Particularly, the introduc-
tion of so-called “high-sensitivity” cTn (hs-cTn) mea-
surements should be pursued using only well-validated
assays; the use of assays before their robust analytical and
clinical validation should be discouraged (2 ). Laboratory
personnel should know their cTn assay performance
characteristics and the preanalytical prerequisites for ro-
bustness to ensure optimal postanalytical reporting. In
this issue of Clinical Chemistry, Wu et al. (3 ) highlight
many important laboratory aspects of hs-cTn measure-
ment. The document represents a laudable attempt by a
group of laboratory experts to inform colleagues about
these issues and to offer recommendations for improving
current measurement practice.
Accurate calibration of hs-cTn assays in the low
range of concentrations is of the upmost importance for
clinical applications that rely on a single cTn measure-
ment at admission (2 ). Even relatively small analytical
variations in practice may influence the proportion of
patients who could be identified as suitable for discharge.
Consequently, there are mandatory tools that laborato-
ries would need to use to check the performance at the
low end of measuring ranges of hs-cTn assays. Wu et al.
(3 ) are correct in recommending (a) a low-level quality
controlmaterial with cTn concentration close to the 99th
percentile upper reference limit (URL) to monitor assay
alignment at cutoff, and (b) a patient pool with an hs-cTn
concentration close to the limit of detection (LoD) to
monitor baseline drifts. In addition, long-term monitor-
ing of imprecision across different reagent lots should
also be carried out. I would also recommend that the
calibration frequency should be based on the imprecision
performance and drift characteristics of the specific assay.
According to the consensus established at the 2014
European Federation for Clinical Chemistry and Labo-
ratory Medicine Strategic Conference for setting quality
specifications in laboratory medicine, the best scientific
approach to define analytical performance specifications
(APS) for cTn should rely on data from clinical outcome
studies (4 ). Particularly, cTnAPS can be defined in terms
of permissible misclassification rates. Performing dupli-
cate cTn measurements, Sheehan et al. (5 ) calculated the
frequency with which the result of the second replicate
fell in a different diagnostic group, thus defining the per-
centage of misclassified patients with suspected AMI
based on assay imprecision. Recently, Lyon et al. (6 ) have
applied a simulation model for estimating the misclassi-
fication rate of patients with suspected AMI when an
hs-TnI assay in conjunction with its 99th percentile
URL is used. A false-positive rate of approximately 1%
was obtained when both bias and imprecision (as CV)
of measurements were kept around 10%. Accordingly,
Wu et al. should have been more decisive in recom-
mending APS for cTn measurement at the concentra-
tion corresponding to the assay 99th percentile URL as
a CV10% and a bias within10%. If a greater bias
than 10% is detected in the quality control, a read-
justment of the measuring system must be undertaken
to decrease it.
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Regarding the reporting units, there was a recom-
mendation from the IFCC supporting the use of nano-
grams per liter and whole numbers to which the authors
did not refer (7 ). It has been demonstrated that the use of
decimal numbers may lead to misinterpretation of test
results and is a potential source of medical errors (8 ).
Therefore, avoiding the unnecessary use of decimals is a
matter of patient safety. Accordingly, it is unclear why the
authors still support the unit option of micrograms per
liter with 2 decimal points when “contemporary” assays
are used. Units for cTn should be harmonized regardless
of the analytical sensitivity of the assay used.
Depending on available resources and capability, it
may not be practically feasible for a laboratory to deter-
mine its own cTn reference interval. It is easier to validate
previously established reference limits that are appropri-
ate for the laboratory. The validation can be done accord-
ing to the Clinical and Laboratory Standards Institute
(document C28-A3c, paragraph 11.2), by examining 20
apparently healthy individuals from a laboratory’s own
subject population (9 ). In selecting these subjects, the
exclusion criteria are of utmost importance. Among the
surrogate biomarkers to be used,Wu et al. suggest relying
on natriuretic peptides, glycohemoglobin, and (esti-
mated) glomerular filtration rate (eGFR) (3 ). However,
they contradict the notion of recommending the selec-
tion of healthy individuals when individuals with predi-
abetes and/or eGFR until 60 mL/min/1.73 m2 will be
included. According to KDIGO 2012 Clinical Prac-
tice Guideline for the Evaluation and Management of
Chronic Kidney Disease (10 ), the 60-mL/min/1.73 m2
limit identifies persons with already mildly decreased
GFR and a possible initial stage of chronic kidney disease.
More importantly, the authors seem to ignore previously
published data in which a slight decrease of eGFR was
associated with a significant increase of hs-cTn. For in-
stance, Martens et al. (11 ) showed that eGFR of 60 to 90
mL/min/1.73 m2 compared with90 mL/min/1.73 m2
was associated with a 1.21 and 1.14 times higher hs-
cTnT and hs-cTnI, respectively. These findings con-
firmed the previously published observations of Bjurman
et al. (12 ).
The improved analytical sensitivity of hs-cTn assays
has reinforced the evidence that the 99th percentile deci-
sion limit, if applied to only 1 result, is not functional to
the diagnosis of AMI, and only serial testing allows for
the discrimination of acute from chronic pathophysio-
logical mechanisms of cTn release (1 ). This is supported
by the evidence of high interindividual biological vari-
ability of cTn, which limits the clinical application of any
fixed cutoff value, and by the wide disagreement between
hs-cTn methods to identify patients above the 99th per-
centile cutoff (13 ). In contrast with this evidence, Wu et
al. seem to put too much emphasis on the concept of
URL, including the long discussion about the need
(or not) of sex-partitioned thresholds, leaving the central
issue of the high individuality of the biomarker confined
to a short sentence in the last paragraph of the document.
The authors’ definition of hs-cTn assays (see rec-
ommendation 5) is subjective. Too many factors are
influencing this definition (e.g., experimental defini-
tion of LoD, selection of population). Approaches us-
ing evidence-based information instead of those based on
the number of healthy subjects with cTn  LoD are
preferable. The UK National Institute for Health and
Care Excellence guideline is a nice example, considering
the available literature supporting the presumed high
clinical sensitivity of the evaluated assays in a clinical
setting (i.e., the ability to rule out AMI at hospital admis-
sion) (14 ). The National Institute for Health and Care
Excellence guideline showed that the Beckman Coulter
assay, even if fulfilling the Wu et al. criteria of50% of
healthy values above LoD, could not be recommended at
the time of guide release because robust scientific clinical
data were lacking. On the other hand, according to the
approach of Wu et al. (3 ), an assay like the Roche Diag-
nostics Gen 5 cTnT, whose clinical performance is sup-
ported by an enormous amount of data (14 ), would not
be able to meet their recommendation (15 ). Overall, the
need of a definition of “high-sensitivity” cTn assays is
scientifically questionable. In the near future, even more
analytically sensitive cTn assays will certainly be devel-
oped, thus making any absolute high sensitivity designa-
tion obsolete. In perfect agreement with this view, the US
Food and Drug Administration decided not to use the
high sensitivity terminology when cTnT Gen 5 received
clearance in January 2017.
During the past decade, the analytical performance
of cTn assays has been continuously improving: Com-
parison of different generation assays clearly shows that
there has been a marked improvement in the quality of
the measurement offered by the newer assays. With some
exceptions discussed in this editorial, the suggestions re-
ported byWu et al., if correctly applied, can contribute to
alleviate inconsistencies and confusion that may exist for
hs-cTn assays. To avoid the possibility for misinterpreta-
tion of a cTn result for patient care, one always has to
keep in mind that the performance characteristics of the
assays used should be adequately described. Clinical
stakeholders who rely heavily on cTn measurement in
medical decision-making will be substantially impacted
by the quality of information regarding the assays used in
clinical laboratories.
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